Mirum Pharmaceuticals Inc. - notizie pubblicate 214 - letture 2.272
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that on may 10, 2024, the compensation committee of mirum's board of directors gra ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- first quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million - fda approval of livmarli for cholestatic pruritus in pfic pati ...
MIRUM PHARMACEUTICALS INC.
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
Mirm-20240331 table of contents united states securities and exchange commission washington, d.c. 20549 ____________________________________________________________________________ ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update - Form 8-K
Mirum pharmaceuticals reports first quarter 2024 financial results and provides business update •first quarter 2024 total revenue of $69.2 million, on track to achieve full-year ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm), a biopharmaceutical company focused on the identification, acquisition, development and commercia ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm), a biopharmaceutical company focused on the identification, acquisition, development and commercia ...
MIRUM PHARMACEUTICALS INC.
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
- data demonstrate significant benefit across broadest range of genetic pfic types ever studied - significant improvements observed across multiple parameters including pruritus, s ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that it will report first quarter 2024 financial results on may 8, 2024. mirum wil ...
MIRUM PHARMACEUTICALS INC.
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer mirum pharmaceuticals inc. published t ...
MIRUM PHARMACEUTICALS INC.
Proxy Statement - Form DEF 14A
Document table of contents united states securities and exchange commission washington, d.c. 20549 schedule 14a information proxy statement pursuant to section 14(a) of the securit ...
MIRUM PHARMACEUTICALS INC.
Additional Proxy Soliciting Materials - Form DEFA14A
Document united states securities and exchange commission washington, d.c. 20549 schedule 14a information proxy statement pursuant to section 14(a) of the securities exchange act o ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that on april 10, 2024, the compensation committee of mirum's board of directors g ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- positive hta recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder - livmarli is the f ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti